West Pharmaceutical Services (WST) is scheduled to release first-quarter 2025 results on April 24, before the opening bell. In the last reported quarter, the company delivered an earnings beat of 4.00%. WST’s earnings beat estimates in three of the trailing four quarters and missed once, delivering an average surprise of 8.33%.Q1 EstimatesCurrently, the Zacks Consensus Estimate for revenues is pegged at $686.5 million, indicating a decline of 1.3% from the year-ago period’s level. The consensus mark for ear ...

West Pharmaceutical Services (WST) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The earnings report, which is expected to be released on April 24, 2025, might help the stock move higher if these key numbers are b ...

Company Overview - West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services, supporting both established and emerging drug developers [4] - The company has over 10,000 team members across 50 sites, including 25 manufacturing facilities worldwide, delivering over 41 billion components and devices each year [4] Financial Performance - In fiscal year 2024, West generated $2.89 billion in net sales [5] - The company is traded on the New York Stock Exchange (NYSE: WST) and is included in the Standard & Poor's 500 index [5] Upcoming Events - West will release its first-quarter financial results before the market opens on April 24, 2025, followed by a conference call at 9:00 a.m. Eastern Time [1] - A slide presentation will be available on the company's website on the day of the call, and a replay of the conference call and webcast will be accessible for approximately 90 days after the event [3]

I have not written anything related to West Pharmaceutical Services (NYSE: WST ) since May of 2024. Since then, the company has had a lumpy year. The underperformance against the index has been evident. In this article, I will try toQuality Growth Investor. I have the simplest of tastes, I only like the best. Here I will analyze the companies in my investment universe. I am looking for the best businesses in the world in order to create a long term portfolio that can outperform the market.Analyst’s Disclosu ...

EXTON, Pa., Feb. 20, 2025  /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, announced today that the Company's Board of Directors has approved a second-quarter 2025 dividend of $0.21 per share. The dividend will be paid on May 7, 2025, to shareholders of record as of April 30, 2025.About West  West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a t ...

Customer Concentration - The company's ten largest customers accounted for 43.4% of consolidated net sales in 2024, with one customer contributing 12.3% or $356.4 million[34] - The company reported that its ten largest customers accounted for 43.4% of consolidated net sales in 2024, with one customer contributing 12.3% or $356.4 million[34] Intellectual Property Development - In 2024, more than 170 utility and design patents were issued globally, indicating a strong focus on intellectual property development[27] - In 2024, the company was issued more than 170 utility and design patents globally, indicating a strong focus on intellectual property development[27] Employee Statistics - Approximately 10,600 employees were employed as of December 31, 2024, with an attrition rate of approximately 17% during the year[43] - The company employed approximately 10,600 people as of December 31, 2024, with an attrition rate of approximately 17% during the year[43] - The company has a global gender demographic of 63% men and 37% women among its employees as of December 31, 2024[43] - The company has a global gender demographic of 63% men and 37% women among its employees as of December 31, 2024[43] Supply Chain Management - The company has implemented a supply chain management strategy that relies on single-source suppliers for many critical raw materials, increasing supply chain risk[25] - The company has a supply chain management strategy that relies on single-source suppliers for many critical raw materials, which increases supply chain risk[25] Regulatory Compliance - Compliance with government regulations did not require material capital expenditures in 2024 and is not expected to impact 2025 significantly[29] - The company has not incurred material capital expenditures for compliance with government regulations in 2024 and does not expect significant expenditures in 2025[29] Strategic Initiatives - The company continues to pursue strategic initiatives in drug containment components and integrated drug delivery systems, focusing on innovation and market expansion[42] - The company continues to pursue strategic initiatives in drug containment components and integrated drug delivery systems, focusing on innovation and partnerships[42] Environmental, Social, and Governance (ESG) - The company is committed to enhancing its Environmental, Social, and Governance (ESG) framework, focusing on sustainability and compliance with regulatory requirements[50] - The company has committed to a climate and greenhouse gas reduction strategy, focusing on renewable energy and reducing emissions[50] Employee Retention and Rewards - The company has a comprehensive total rewards program aimed at attracting and retaining high-performing team members, reflecting the value of their contributions[47] - The company has a comprehensive total rewards program aimed at attracting and retaining high-performing team members[47] Health, Safety, and Wellness - The company maintains a strong focus on health, safety, and wellness, with dedicated teams at each manufacturing location to ensure compliance and safety[48]

Robert F. Abbott has been investing his family’s accounts since 1995, and in 2010 added options, mainly covered calls and collars with long stocks. He is a freelance writer, and his projects include a website that provides information for new and intermediate-level mutual fund investors. A resident of Airdrie, Alberta, Canada, Robert has earned Bachelor of Arts and Master of Business Administration (MBA) degrees.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the co ...

UKRAINE - 2021/02/08: In this photo illustration a West Pharmaceutical Services logo seen on a ... [+] mobile phone and a pc screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesWest Pharmaceutical Services, a global provider of solutions for drugs, biologics, gene therapies, and consumer healthcare products, recently announced its Q4 results, surpassing analysts' expectations for both revenue and earnings. The company reported sales o ...

Fourth Quarter Overall Net Sales $748.8M | 2.3% Diluted Earnings Per Share: $1.78 Adjusted Diluted Earnings Per Share: $1.82 "I am pleased to report we had a strong quarter with revenues and profits exceeding our expectations, and a return to positive organic growth as the impact of destocking continues to moderate. Our core businesses continue to benefit from our market-leading positions and proprietary processes. Looking ahead to 2025, we expect our business momentum to continue in key areas of our Propri ...

West Pharmaceutical Services, Inc. (NYSE:WST) Q4 2024 Earnings Conference Call February 13, 2025 9:00 AM ET Company Participants John Sweeney - Vice President of Investor Relations Eric Green - Chairman, President & Chief Executive Officer Bernard Birkett - Senior Vice President & Chief Financial Officer Conference Call Participants Michael Ryskin - BofA Global Research Lawrence Solow - CJS Securities Patrick Donnelly - Citigroup Inc. Paul Knight - KeyBanc Capital Markets Matthew Larew - William Blair & Com ...